Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...

South Korean biopharmaceutical firm Celltrion said Tuesday that it had released its denosumab biosimilars, Stoboclo and ...

Biotechnology corporation Celltrion has expressed its intention to appeal the judgment regarding the 'COVID-19 diagnostic kit lawsuit' against domestic in vitro diagnostic corporation Humasis. On the ...

LONDON, June 19, 2025--Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company’s dedication to long-term growth and ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

SEOUL, July 4 (Yonhap) -- Celltrion Holdings, the holding company of Celltrion Group, a leading South Korean pharmaceutical conglomerate, said Friday it will purchase 500 billion won (US$366 million) ...

Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...

Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company’s dedication to long-term growth ...